MindBio Therapeutics (MBIO.CN) Action Cours

MindBio Therapeutics Corp, listed under the ticker MBIO.CN with ISIN CA60256C2076, is a company based in Vancouver, Canada. It went public through an IPO on May 5, 2023. The company focuses on developing psychedelic-based medicines to address various medical conditions, including depression, anxiety, PTSD, panic disorder, chronic pain, and opiate addictions. MindBio Therapeutics is engaged in clinical trials involving lysergic acid diethylamide (LSD) microdosing, having completed Phase I trials with 80 patients. The company is currently developing Phase II trials for LSD microdosing in patients with major depressive disorder and in late-stage cancer patients experiencing existential distress. It operates with a multi-disciplinary platform aimed at creating novel treatments for mental health conditions. MindBio Therapeutics emphasizes research into digital technologies and interventions as part of its strategy to develop clinically proven treatments for debilitating health conditions such as depression and anxiety. The company’s website is www.mindbiotherapeutics.com. It does not specify a sector or industry classification. The firm’s activities are centered on advancing psychedelic medicine development, with a focus on both clinical research and therapeutic innovation.